140 related articles for article (PubMed ID: 16212319)
1. Current diagnosis and treatment of oligodendroglioma.
Engelhard HH
Neurosurg Focus; 2002 Feb; 12(2):E2. PubMed ID: 16212319
[TBL] [Abstract][Full Text] [Related]
2. Oligodendroglioma: pathology and molecular biology.
Engelhard HH; Stelea A; Cochran EJ
Surg Neurol; 2002 Aug; 58(2):111-7; discussion 117. PubMed ID: 12453646
[TBL] [Abstract][Full Text] [Related]
3. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
4. Advances in diagnosis and management of oligodendroglioma.
Hussein MR; Baidas S
Expert Rev Anticancer Ther; 2002 Oct; 2(5):520-8. PubMed ID: 12382520
[TBL] [Abstract][Full Text] [Related]
5. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.
Bauman GS; Ino Y; Ueki K; Zlatescu MC; Fisher BJ; Macdonald DR; Stitt L; Louis DN; Cairncross JG
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):825-30. PubMed ID: 11020580
[TBL] [Abstract][Full Text] [Related]
6. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
[TBL] [Abstract][Full Text] [Related]
7. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
[TBL] [Abstract][Full Text] [Related]
8. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
Engelhard HH; Stelea A; Mundt A
Surg Neurol; 2003 Nov; 60(5):443-56. PubMed ID: 14572971
[TBL] [Abstract][Full Text] [Related]
9. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
Cairncross G; Jenkins R
Cancer J; 2008; 14(6):352-7. PubMed ID: 19060598
[TBL] [Abstract][Full Text] [Related]
10. The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
Kanner AA; Staugaitis SM; Castilla EA; Chernova O; Prayson RA; Vogelbaum MA; Stevens G; Peereboom D; Suh J; Lee SY; Tubbs RR; Barnett GH
J Neurosurg; 2006 Apr; 104(4):542-50. PubMed ID: 16619658
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors.
Sankar T; Moore NZ; Johnson J; Ashby LS; Scheck AC; Shapiro WR; Smith KA; Spetzler RF; Preul MC
J Neurosurg; 2012 Jun; 116(6):1172-81. PubMed ID: 22424566
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review.
Da Fonseca CO; Masini M; Futuro D; Caetano R; Gattass CR; Quirico-Santos T
Surg Neurol; 2006 Dec; 66(6):611-5. PubMed ID: 17145324
[TBL] [Abstract][Full Text] [Related]
13. A 31-year-old woman with a transformed low-grade glioma.
Warnke PC
JAMA; 2010 Mar; 303(10):967-76. PubMed ID: 20159860
[TBL] [Abstract][Full Text] [Related]
14. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.
Perry A; Fuller CE; Banerjee R; Brat DJ; Scheithauer BW
Front Biosci; 2003 Jan; 8():a1-9. PubMed ID: 12456321
[TBL] [Abstract][Full Text] [Related]
15. Oligodendroglioma.
Mason WP
Curr Treat Options Neurol; 2005 Jul; 7(4):305-314. PubMed ID: 15967093
[TBL] [Abstract][Full Text] [Related]
16. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
17. [Significance and prospects of study on molecular alterations in oligodendrogliomas].
Gresner SM; Liberski PP
Neurol Neurochir Pol; 2007; 41(4):333-9. PubMed ID: 17874342
[TBL] [Abstract][Full Text] [Related]
18. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
Michaud K; de Tayrac M; D'Astous M; Duval C; Paquet C; Samassekou O; Gould PV; Saikali S
PLoS One; 2016; 11(12):e0168728. PubMed ID: 28030632
[TBL] [Abstract][Full Text] [Related]
19. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component.
Walker C; du Plessis DG; Fildes D; Haylock B; Husband D; Jenkinson MD; Joyce KA; Broome J; Kopitski K; Prosser J; Smith T; Vinjamuri S; Warnke PC
Clin Cancer Res; 2004 Nov; 10(21):7182-91. PubMed ID: 15534091
[TBL] [Abstract][Full Text] [Related]
20. The changing management of low-grade astrocytomas and oligodendrogliomas.
Agulnik M; Mason WP
Hematol Oncol Clin North Am; 2006 Dec; 20(6):1249-66. PubMed ID: 17113461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
